February 26, 2018 12:52pm
Volatility, algorithms, ETFs and cash positions along with who needs to “tap” the capital markets for continued survival?
How are enrollments going as to population and are they sustainable re drop-outs? Has the data from on-going trials been interpreted as to render measurable and definitive outcomes? Is the company partnered to ward-off the issues of dilution and share depreciation!
And finally, trend analysis – do momentum’s magnitude, technicals and fundamentals indicate expected pricing performance in 2018?
Why spend time finding sector news and analytics … it’s all right here! Review daily indicators, relative strength factors and trend lines, advance/decline lines, pre-open indicator results, volatility and of the % count of decliners versus gainers.
Learn who is stumbling and what the mumbling means …
For 8 years, RMi is the only source of actionable intelligence for the stem, cell and gene therapy and regenerative medicine’s universe.
You’ve enjoyed complimentary access to unbiased analysis, in-depth analytics, and informational synthesis along with RMi’s review of “our” universe’s stocks and their potential for gains and losses. Access to RegMed Investors’ targeted content is by subscription.
For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below:
